162 related articles for article (PubMed ID: 21159366)
1. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
Tait DL; Blessing JA; Hoffman JS; Moore KN; Spirtos NM; Lachance JA; Rotmensch J; Miller DS
Gynecol Oncol; 2011 Apr; 121(1):118-21. PubMed ID: 21159366
[TBL] [Abstract][Full Text] [Related]
2. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
Miller DS; Blessing JA; Drake RD; Higgins R; McMeekin DS; Puneky LV; Krasner CN
Gynecol Oncol; 2009 Dec; 115(3):443-6. PubMed ID: 19804902
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Schilder RJ; Blessing J; Cohn DE
Gynecol Oncol; 2005 Jan; 96(1):103-7. PubMed ID: 15589587
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.
Look KY; Sandler A; Blessing JA; Lucci JA; Rose PG;
Gynecol Oncol; 2004 Feb; 92(2):644-7. PubMed ID: 14766260
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.
Grisham RN; Adaniel C; Hyman DM; Ma W; Iasonos A; Aghajanian C; Konner J
Int J Gynecol Cancer; 2012 Jun; 22(5):807-11. PubMed ID: 22635030
[TBL] [Abstract][Full Text] [Related]
6. Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Suprasert P; Cheewakriangkrai C; Manopunya M
Asian Pac J Cancer Prev; 2012; 13(2):517-20. PubMed ID: 22524817
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group.
Schilder RJ; Blessing JA; Morgan M; Mangan CE; Rader JS
Gynecol Oncol; 2000 Feb; 76(2):204-7. PubMed ID: 10637071
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients.
Bilgin T; Ozalp S; Yalçin OT; Zorlu G; Vardar MA; Ozerkan K
Eur J Gynaecol Oncol; 2003; 24(2):169-70. PubMed ID: 12701971
[TBL] [Abstract][Full Text] [Related]
9. Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.
Safra T; Ron I; Boaz M; Brenner J; Grisaru D; Inbar M; Hayat H; Menczer J; Golan A; Levy T
Acta Oncol; 2006; 45(4):463-8. PubMed ID: 16760183
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
11. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
12. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
13. NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).
Gertler SZ; MacDonald D; Goodyear M; Forsyth P; Stewart DJ; Belanger K; Perry J; Fulton D; Steward W; Wainman N; Seymour L
Ann Oncol; 2000 Mar; 11(3):315-8. PubMed ID: 10811498
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Look KY; Blessing JA; Michener CM; Rubin S; Ramirez PT;
Int J Gynecol Cancer; 2008; 18(4):773-8. PubMed ID: 17892452
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.
Hoang T; Kim K; Jaslowski A; Koch P; Beatty P; McGovern J; Quisumbing M; Shapiro G; Witte R; Schiller JH
Lung Cancer; 2003 Oct; 42(1):97-102. PubMed ID: 14512193
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Calvert SW; Willcutt NT; Scullin DC; Bramham J; Greco FA
Cancer Invest; 2001; 19(4):335-9. PubMed ID: 11405172
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
D'Agostino G; Amant F; Berteloot P; Scambia G; Vergote I
Gynecol Oncol; 2003 Mar; 88(3):266-9. PubMed ID: 12648573
[TBL] [Abstract][Full Text] [Related]
19. Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).
Ferrigno D; Buccheri G;
Lung Cancer; 2004 Sep; 45(3):373-80. PubMed ID: 15301878
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Goff BA; Holmberg LA; Veljovich D; Kurland BF;
Gynecol Oncol; 2008 Aug; 110(2):146-51. PubMed ID: 18538834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
